CST3 and Alzheimer disease: The increase of this cathepsin-inhibitory enzyme in AD patients may represent a compensatory activity aimed at counteracting the increased presence of cathepsin D. Cystatin C levels were also increased in response to injury and oxidative stress (Finckh et al., 2000; Nishio et al., 2000).